Pasithea Historical Financial Ratios

KTTA Stock  USD 2.66  0.03  1.14%   
Pasithea Therapeutics is promptly reporting on over 84 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Pasithea Therapeutics financial condition quickly.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About Pasithea Financial Ratios Analysis

Pasithea TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Pasithea Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Pasithea financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Pasithea Therapeutics history.

Pasithea Therapeutics Financial Ratios Chart

At present, Pasithea Therapeutics' Book Value Per Share is projected to increase significantly based on the last few years of reporting. The current year's Cash Per Share is expected to grow to 17.12, whereas Free Cash Flow Yield is projected to grow to (1.37).
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Pasithea Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Pasithea Therapeutics sales, a figure that is much harder to manipulate than other Pasithea Therapeutics Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Stock Based Compensation To Revenue

A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.
Most ratios from Pasithea Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Pasithea Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
At present, Pasithea Therapeutics' Book Value Per Share is projected to increase significantly based on the last few years of reporting. The current year's Cash Per Share is expected to grow to 17.12, whereas Free Cash Flow Yield is projected to grow to (1.37).
 2010 2022 2023 (projected)
PB Ratio203.230.380.4
Capex To Depreciation15.5966.065.3E-5

Pasithea Therapeutics fundamentals Correlations

0.83-0.570.990.49-0.93-0.180.83-1.00.980.950.990.74-0.850.74-0.91-0.45-0.621.00.5-0.830.970.710.88-0.88-0.83
0.83-0.920.840.54-0.77-0.151.0-0.830.90.880.870.61-0.710.61-0.75-0.86-0.910.830.42-1.00.80.390.63-0.98-1.0
-0.57-0.92-0.56-0.650.450.32-0.920.57-0.7-0.61-0.61-0.30.37-0.30.580.990.99-0.55-0.480.91-0.50.01-0.270.820.91
0.990.84-0.560.37-0.97-0.030.84-0.990.960.981.00.81-0.920.81-0.86-0.45-0.591.00.36-0.840.990.780.93-0.91-0.84
0.490.54-0.650.37-0.15-0.910.54-0.490.610.280.41-0.130.01-0.13-0.68-0.58-0.760.420.97-0.540.27-0.240.03-0.4-0.54
-0.93-0.770.45-0.97-0.15-0.19-0.770.93-0.88-0.98-0.96-0.910.99-0.910.730.350.45-0.96-0.150.77-0.99-0.88-0.980.870.77
-0.18-0.150.32-0.03-0.91-0.19-0.150.18-0.280.1-0.070.44-0.350.440.440.260.45-0.09-0.940.150.070.470.260.00.15
0.831.0-0.920.840.54-0.77-0.15-0.830.90.880.870.61-0.710.61-0.75-0.86-0.910.830.42-1.00.80.390.63-0.98-1.0
-1.0-0.830.57-0.99-0.490.930.18-0.83-0.98-0.95-0.99-0.740.86-0.740.910.450.62-1.0-0.50.83-0.97-0.71-0.880.880.83
0.980.9-0.70.960.61-0.88-0.280.9-0.980.930.970.67-0.790.67-0.91-0.59-0.750.970.58-0.90.930.580.8-0.91-0.9
0.950.88-0.610.980.28-0.980.10.88-0.950.930.980.85-0.950.85-0.79-0.52-0.610.970.24-0.880.990.780.93-0.95-0.88
0.990.87-0.611.00.41-0.96-0.070.87-0.990.970.980.81-0.910.81-0.86-0.51-0.641.00.4-0.870.990.740.91-0.93-0.88
0.740.61-0.30.81-0.13-0.910.440.61-0.740.670.850.81-0.951.0-0.4-0.25-0.260.8-0.14-0.610.860.880.89-0.74-0.62
-0.85-0.710.37-0.920.010.99-0.35-0.710.86-0.79-0.95-0.91-0.95-0.950.620.290.36-0.90.020.71-0.96-0.92-0.980.830.71
0.740.61-0.30.81-0.13-0.910.440.61-0.740.670.850.811.0-0.95-0.4-0.25-0.260.8-0.14-0.610.860.880.89-0.74-0.62
-0.91-0.750.58-0.86-0.680.730.44-0.750.91-0.91-0.79-0.86-0.40.62-0.40.440.67-0.87-0.70.75-0.81-0.47-0.690.750.76
-0.45-0.860.99-0.45-0.580.350.26-0.860.45-0.59-0.52-0.51-0.250.29-0.250.440.96-0.43-0.380.86-0.390.1-0.160.760.86
-0.62-0.910.99-0.59-0.760.450.45-0.910.62-0.75-0.61-0.64-0.260.36-0.260.670.96-0.59-0.610.91-0.520.02-0.280.810.91
1.00.83-0.551.00.42-0.96-0.090.83-1.00.970.971.00.8-0.90.8-0.87-0.43-0.590.42-0.830.990.760.92-0.89-0.83
0.50.42-0.480.360.97-0.15-0.940.42-0.50.580.240.4-0.140.02-0.14-0.7-0.38-0.610.42-0.420.27-0.170.07-0.3-0.42
-0.83-1.00.91-0.84-0.540.770.15-1.00.83-0.9-0.88-0.87-0.610.71-0.610.750.860.91-0.83-0.42-0.81-0.39-0.640.981.0
0.970.8-0.50.990.27-0.990.070.8-0.970.930.990.990.86-0.960.86-0.81-0.39-0.520.990.27-0.810.840.96-0.89-0.81
0.710.390.010.78-0.24-0.880.470.39-0.710.580.780.740.88-0.920.88-0.470.10.020.76-0.17-0.390.840.95-0.56-0.39
0.880.63-0.270.930.03-0.980.260.63-0.880.80.930.910.89-0.980.89-0.69-0.16-0.280.920.07-0.640.960.95-0.76-0.64
-0.88-0.980.82-0.91-0.40.870.0-0.980.88-0.91-0.95-0.93-0.740.83-0.740.750.760.81-0.89-0.30.98-0.89-0.56-0.760.98
-0.83-1.00.91-0.84-0.540.770.15-1.00.83-0.9-0.88-0.88-0.620.71-0.620.760.860.91-0.83-0.421.0-0.81-0.39-0.640.98
Click cells to compare fundamentals

Pasithea Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(14.79)
Revenue Per Share
0.37
Quarterly Revenue Growth
14.981
Return On Assets
(0.38)
Return On Equity
(0.63)
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.